Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3605570 | 0.84 | MTNR1B (0.48) | MTNR1BTP53MAPT | |
| SCHEMBL3611801 | 0.79 | MTNR1B (0.44) | MTNR1BTP53SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL3609833 | 0.79 | GHSR (0.49) | HTTNCOA1SMN1; SMN2NCOA3MAPT | |
| SCHEMBL3612271 | 0.79 | KMT2A (0.36) | MTNR1BTP53HTTSMN1; SMN2MAPT | |
| SCHEMBL3617478 | 0.77 | GHSR (0.45) | HTTNCOA1SMN1; SMN2NCOA3SIGMAR1 | |
| SCHEMBL3615470 | 0.75 | MTNR1B (0.47) | MTNR1BSMN1; SMN2MAPTSIGMAR1LMNA | |
| SCHEMBL3617388 | 0.74 | MTNR1B (0.41) | MTNR1BTP53MAPT | |
| SCHEMBL3606601 | 0.72 | XIAP (0.42) | MTNR1B | |
| SCHEMBL11119714 | 0.69 | MTNR1B (0.56) | MTNR1BTP53SMN1; SMN2MAPT | |
| SCHEMBL31011341 | 0.69 | CA1 (0.55) | HTTMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-1857444-A1 | TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | ACAT1, ACAT2, LCAT | MTNR1B 2142/4885TP53 1800/4885HTT 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.